Browse our latest media releases, coverage, videos and events!
Atturos presents latest data from GRAPPA-Pfizer study at ACR Convergence 2022, Philadelphia, USA
11th November 2022
Atturos CSO Steve Pennington presented the latest data obtained as part of on-going GRAPPA-Pfizer study at the American College of Rheumatology Meeting (ACR Convergence) held in Philadelphia, USA 11-14th November. The poster presentation on “Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis” outlined the development of a blood protein signature measured by MRM and associated algorithm that may be predict which patients will respond to JAK inhibitor treatment.
To view the full abstract click the link below:
Neoteryx microsamplify podcast series: microsampling in proteomics & multi-center studies
17th January 2022
The recently started HIPPOCRATES EU consortium and Government of Ireland (DTIF) project, PERSONA, will see Atturos working with Neoteryx to investigate microsampling devices for use in protein based advanced diagnostic testing. In this podcast, Atturos CSO Steve Pennington discusses the use of microsampling in proteomics & multi-centre studies.
Oliver FitzGerald recognised as ACR Master
2nd September 2021
Oliver FitzGerald (Atturos Clinical Leadership Team and GRAPPA Co-President) has been recognised as a Master of the American College of Rheumatology. This is one of the highest honours the College bestows to members who have made outstanding contributions to the field of rheumatology through scholarly achievement and/or service to their patients, students, and profession. Congratulations Oliver!
Atturos to play a key role in HIPPOCRATES - a new €21m EU and industry funded research project
2nd July 2021
HIPPOCRATES combines 26 different research partners, SMEs, pharmaceutical companies, and patient organisations in promoting early identification and improving outcomes for patients with psoriatic arthritis. The consortium is co-led by Stephen Pennington, Atturos CSO, and Oliver FitzGerald, Atturos Head of Clinical Affairs Rheumatology. Download a copy of the full press release here, and visit the website for more information
Atturos features in the Business Post’s ‘Making it Work’
24th June 2021
Atturos recent funding successes and the future directions of our product development have appeared in a Sunday Business Post article ‘Making it Work: Medical start-up Atturos gets €700k for arthritic research’. In the article Steve, Atturos founder and CSO, discusses the next stages in Atturos business development including the recruitment of a CEO. To read the article click below.
Atturos Led Consortium Awarded €1.57m to Develop PERSONA
22nd April 2021
Atturos is delighted to announce it has secured €1.57m funding from the third round of the Disruptive Technologies Innovation Fund. In collaboration with Agilent Technologies Ireland, Neoteryx and UCD, the consortium will develop the first innovative plasma sampling device for inflammatory diseases. We are excited to move PERSONA (Patient Centric Sampling for a New Diagnostic Pathway) forward, and look forward to updating you all soon with further information!
Atturos Christmas Tree Lights Switch On!
1st December 2020
We all know it's been a challenging year, so we used the 1st of December as an excuse to decorate the office, put on our festive jumpers and switch on the Atturos office Christmas tree lights! Thanks to our fantastic research assistant Joy for doing the honours.
Patent granted for OCProDx in the United States of America
17th November 2020
Following the grant of the “Prostate Cancer Biomarkers” patent in Europe, Atturos have now been granted a US wide patent (US 15/106,582) derived from International patent application (PCT/EP2014/078914).
Scientific Paper published in BMC Clinical Proteomics
21st October 2020
Read our latest publication "A robust multiplex immunoaffinity mass spectrometry assay (PromarkerD) for clinical prediction of diabetic kidney disease". This work represents a collaborative effort between the Atturos Team, Proteomics International (Perth) and Sydney Mass Spectrometry.
New Atturos Website Launched
25th September 2020
As our team and portfolio are quickly expanding, our website needed to grow with us... welcome to the new look website! If you have any feedback, please let us know!
100 Hot Start Ups – Sunday Business Post
30th September 2019
Atturos Ltd is delighted to be recognised amongst The Sunday Business Post’s latest list of Irish entrepreneurial companies.
Proteomics International and Atturos Partner to Target Diagnostics in Europe
19th September 2018
Proteomics International and Irish clinical diagnostics company Atturos have signed a Memorandum of Understanding that will see the companies join forces to develop novel diagnostic tests for the European region.
Atturos Host Clinical and Technical Brainstorming Sessions with Key Opinion Leaders
16th May 2016
Last Friday May 13th Atturos hosted a Clinical and Technical Brainstorming session in NovaUCD as part of our market analysis to obtain and evaluate customer and end user attitudes towards the OCProDx test...
Atturos: Better diagnostics through machine learning analytics
25th July 2022
We’re delighted to have been profiled by Silicon Republic, Ireland’s No 1 resource for science and technology news, updating on our recent activities and future direction. Atturos CEO Robert Perryman and CSO Steve Pennington share their vision for the future of clinical diagnostics, and how Atturos plans to help patients and doctors with their decision-making.
Atturos moves into a new dedicated office space
5th January 2022
In 2021 Atturos secured additional funding which has resulted in the generation of several new roles within the company. To facilitate the expansion of the team the Atturos office has now relocated to a new, larger, dedicated space.
To view current job opportunities visit our careers page!
WEBINAR: The Agilent and Atturos pathway for the development of targeted biomarker measurements for precision medicine
25th August 2021
“In this expert webinar, Prof. Stephen Pennington, Dr. Orla Coleman, and Dr. James Waddington outline the importance of better diagnostic tests and data to address unmet clinical needs in chronic diseases. They explain how this diagnostic data can be obtained through an integrated workflow that enables simplified, robust, reproducible, and cost-effective analysis of readily collected human samples. Using supporting illustrative data, the Atturos team demonstrate how it will be possible to use clinical research measurements for precision medicine”
Atturos Senior Scientist presents at the International Federation of Psoriasis Associations (IFPA) World Psoriasis & Psoriatic Arthritis Conference (WPPAC)
2nd July 2021
Orla Coleman, Atturos Senior Scientist, presented results from the recently completed Atturos GRAPPA- Lilly project “Identification of serum protein biomarkers at baseline to distinguish radiographic progressors from non-progressors in patients with active Psoriatic Arthritis” at the IFPA 6th WPPAC. Orla’s presentation introduced the unmet clinical need to identify Psoriatic arthritis patients who are risk of progression to radiographic damage. The presentation outlines the work Atturos has undertaken to use targeted proteomics and data analysis by machine learning methods to identify a biomarker signature and algorithm that may predict disease progression.
Article Featured in Clinical Laboratory International
21st June 2021
Led by Atturos CSO Steve Pennington, with contributions from Senior Scientist James Waddington, ‘Biomarkers for improved management of prostate cancer’ has been selected as a feature article in Clinical Laboratory International (CLI). The article describes challenges in the clinical management of prostate cancer, limitations to current screening and diagnostic strategies and the future of biomarker tests for personalized prostate cancer patient care. To read the full article download a copy here, or click on the link below to visit CLI
Prostate Cancer Review Selected as Feature Article
18th January 2021
BMC Clinical Proteomics, part of Springer Nature, selected "Clinical proteomics for prostate cancer" as the feature article for January and February 2021. The review, led by Atturos CSO Steve Pennington, discusses high throughput proteomic technologies as a potential solution for the current challenges faced in diagnosing and treating prostate cancer.
Atturos founder and CSO Stephen Pennington gives key note at PSI 2020
22nd November 2020
Steve presented on the "Development and Delivery of Advanced Protein Tests for an Era of Precision Medicine". For further information on PSI 2020 visit their website!
Atturos Completes Business Case Analysis of Novel Test to Discriminate Psoriatic Arthritis from Rheumatoid Arthritis
16th November 2020
The Atturos management team have undertaken and completed a business case analysis for the commercial feasibility of a serum protein assay – PsARADx. The assay is protected under UCD patent application WO 2020/025721and provides “A method of diagnosing or prognosing psoriatic arthritis”. The analysis undertaken included engagement with key stakeholders. Atturos is now in negotiations with UCD to acquire a license to the patent.
HUPO’s Proteome Project releases the 10-year High‑Stringency Blueprint of the Human Proteome
16th October 2020
Atturos founder, Steve Pennington, and Senior Scientist, James Waddington, played a key role in publication of the Human Proteome Project’s blueprint of the Human Proteome 'A high-stringency blueprint of the human proteome'.
Atturos joins the SOPHIA international research consortium
2nd June 2020
New €16 million EU and industry-supported international research consortium aims to improve obesity treatment and change the narrative around obesity
Twenty-nine leading partners from civil society, academia and industry in 12 countries have joined forces to better understand obesity and optimise future treatment
Poster Presented at the 18th Annual HUPO Congress in Adelaide, Australia.
18th September 2019
Orla Coleman (Atturos) and Scott Bringans (PILL) present the poster "PromarkerD as an immunoaffinity mass spectrometry assay for diabetic kidney disease"
European wide patent granted for OCProDx
17th July 2019
Atturos are pleased to announce that the European patent filing (EP3084444) derived from International patent application (PCT/EP2014/078914) for “Prostate Cancer Biomarkers” has been granted. The patent supports the on-going protection of OCProDx.
Atturos partners with SCREENED H2020 consortium
16th January 2019
The new European collaborative project SCREENED aims to develop three-dimensional (3D)
cellbased in vitro tests to better characterize the effects of endocrine disruptors on thyroid gland function.
OCProDx showcased at Enterprise Ireland’s Big Ideas 2018
5th September 2018
Twelve start-ups pitched their new technology solutions to investors at the 10th annual innovation showcase event BIG IDEAS. Atturos were shortlisted and presented OCProDx to an invited audience of Irish research and business communities
Atturos presents at Oxford Global 13th Annual Biomarkers Congress in Manchester, U.K.
16th February 2018
Steve Pennington invited to join Oxford Global Biomarkers Directors Club and presents at 13th Annual Congress, Manchester, U.K.
Agilent Technologies Lunchtime Workshop at MSACL Annual Conference, Palm Springs, California, U.S.A.
24th January 2018
Atturos development and delivery of MassSpec based multiplexed biomarker assays was presented by Steve Pennington at a lunchtime workshop hosted by Agilent at the Mass Spectrometry Applications to the Clinical Lab 10th Annual Conference Palm Springs, California, U.S.A.
Meeting Brief: The 2nd Annual John Fitzpatrick Prostate Cancer Conference 2016
25th April 2016
Members of the Atturos team attended the 2nd Annual John Fitzpatrick Prostate Cancer Conference last week in the Aviva Stadium in Dublin.
ON DEMAND: The Agilent and Atturos pathway for the development of targeted biomarker measurements for precision medicine
16th March 2022
"This webinar explorers challenges faced by clinical researchers seeking to improve chronic disease testing. Hear experts form Atturos, a leading clinical diagnostics company, discuss the importance of high-quality clinical data and the role improved analytical workflows and advanced tests play in improving precision medicine outcomes."
Inflammation Nation Podcast on Psoriatic arthritis and HIPPOCRATES
8th October 2021
“In this first episode, Prof Oliver FitzGerald and Atturos CSO Prof Stephen Pennington talk to Gráinne O’Leary about psoriatic arthritis, how it’s diagnosed, its symptoms and impact, and patients’ unmet needs. They also discuss HIPPOCRATES the recently funded IMI (Innovative Medicines Initiative) public private research consortium which aims to address unmet needs in psoriatic disease and develop personalised treatment options for those affected.”
Atturos Team Present GRAPPA-Industry Biomarker Project Updates at GRAPPA 2021
8th July 2021
Steve Pennington (Atturos CSO) and Oliver FitzGerald (Atturos Clinical Leadership Team and GRAPPA Co-President) were joined by senior scientists James Waddington and Orla Coleman to present project updates at the international GRAPPA 2021 meeting. The presentation provided GRAPPA network with an update of progress on two important strategic research projects with Lilly and Pfizer.
Atturos CSO Steve Pennington presents Opening Keynote Lecture at Advances in Proteomics & Metabolomics 2021
30th June 2021
Steve was the invited Opening Keynote speaker at TECHNOLOGY NETWORKS, Advances in Proteomics & Metabolomics 2021 – from research to the clinic. The event, attracting over 1,100 registrants, brought together world leading experts to discuss the role of proteomics approaches in understanding disease and the development of novel clinical biomarkers.
Atturos CSO leads research published in Arthritis & Rheumatology
11th June 2021
Read our latest publication “Identification and Evaluation of Serum Protein Biomarkers Which Differentiate Psoriatic from Rheumatoid Arthritis”.
Atturos licenses patent WO 2020/025721 “A method of diagnosing or prognosing psoriatic arthritis” from University College Dublin
11th January 2021
Atturos are pleased to announce that following the completion of a business case analysis, it has negotiated a worldwide exclusive license agreement for patent WO 2020/025721 “A method of diagnosing or prognosing psoriatic arthritis” from University College Dublin. The patent underpins the serum protein ‘PsARADx’ assay which can discriminate patients with psoriatic arthritis from those with rheumatoid arthritis. Atturos is looking forward to beginning the next steps in developing the assay which has the potential to improve psoriatic arthritis patient outcomes.
Review Article Published in BMC Clinical Proteomics
20th November 2020
Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management
Clinical Research Application Note Published in Collaboration with Agilent Technologies
30th October 2020
Read our latest application note "From Nanoflow to Standard Flow LC/MS for Routine Quantitative Plasma Proteomics in Diabetic Kidney Disease Research".
Review Article Published in the
Journal of Molecular Sciences
21st May 2020
SCREENED: A Multistage Model of Thyroid Gland Function for Screening Endocrine-Disrupting Chemicals in a Biologically Sex-Specific Manner
Atturos Presents at CPSA, USA
7th November 2019
Founder and Chief Scientific Officer Prof. Stephen Pennington presents Atturos work at the Clinical and Pharmaceutical Solutions through Analysis Symposium in Philadelphia, Pennsylvania, U.S.A on the 28th of October 2019.
PromarkerD validation study sees transfer to Atturos for EU launch
16th September 2019
Atturos begins collaboration with Merck KGaA, Darmstadt, Germany
23rd April 2018
Atturos is pleased to announce it has begun a significant collaboration with Merck KGaA. “The projects sees Atturos developing important LC-MS workflows for Merck KGaA and marks what both companies hope will be a series of ongoing collaborative projects” notes Dave Corr, CEO Atturos Ltd.
EAU 2016 Annual Meeting
16th March 2016
As part of our continuous clinical and market research efforts Atturos CEO Stephen Pennington attended the European Association of Urology Annual Meeting this past weekend.